<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308906</url>
  </required_header>
  <id_info>
    <org_study_id>Aminoglycoside Waste Specimen</org_study_id>
    <nct_id>NCT00308906</nct_id>
  </id_info>
  <brief_title>Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children</brief_title>
  <official_title>Assessment of Gene and Urinary Protein Expression in Aminoglycoside-treated and Untreated Infants, Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to identify potential gene and protein markers of
      aminoglycoside-induced kidney injury in infants, children and adolescents treated with
      aminoglycoside antibiotics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Indicators of renal injury</measure>
    <time_frame>Pre and post treatment</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">166</enrollment>
  <condition>Infection</condition>
  <condition>Renal Dysfunction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Hospitalized, untreated infants and children</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Aminoglycoside treated infants and children without renal injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Aminoglycoside treated infants with renal injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminoglycoside</intervention_name>
    <description>Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Waste blood samples will be collected in order to evaluate potential genetic mechanisms of
      aminoglyoside induced renal injury. Waste urine samples will be collected in order to
      evaluate candidate protein biomarkers of aminoglycoside induced renal injury.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Aminoglycoside treated and untreated newborns, infants and children.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: (1) Hospitalized male and female newborns, infants, children and
        adolescents (ages birth to 18 years) with a diagnosis of suspected or proven bacterial
        sepsis, meningitis or other indication necessitating aminoglycoside therapy (2)
        hospitalized and outpatient newborns, infants, children and adolescents (ages birth to 18
        years) who are not receiving aminoglycoside therapy.

        Exclusion Criteria: (1) Current treatment with inhaled or ophthalmic aminoglycosides (2)
        Prior treatment with an aminoglycoside within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Jayne Kennedy, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Lousiville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2006</study_first_posted>
  <last_update_submitted>January 30, 2016</last_update_submitted>
  <last_update_submitted_qc>January 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Virginia Commonwealth University</investigator_affiliation>
    <investigator_full_name>Mary Jayne Kennedy</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>infection</keyword>
  <keyword>renal dysfunction</keyword>
  <keyword>aminoglycoside</keyword>
  <keyword>protein</keyword>
  <keyword>child</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

